Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 251 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "HFpEF" Condition: Heart Failure Clear all
Recruiting Phase 2 Interventional

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

NCT07795814
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
30 Years to 84 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

NCT05371496
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
Interventions
Semaglutide, Placebo, Counselling on healthy lifestyle intervention
Drug · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation

NCT06130059
View directory record Official record
Conditions
Heart Failure, Inflammation
Interventions
Low Dose Colchicine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

NCT03837470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Radiofrequency (RF) Ablation for Atrial Fibrillation (AF) in Patients With Heart Failure With Preserved Ejection Fraction

NCT04327596
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

NCT03619213
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
6,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
66
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Dapagliflozin (DAPA) Effects in HFpEF

NCT04730947
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)

NCT02636439
View directory record Official record
Conditions
Heart Failure, Diastolic, Obesity
Interventions
dietary, aerobic and resistance training, dietary, and aerobic exercise
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

NCT06914102
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
58,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 3 Interventional

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001
View directory record Official record
Conditions
Obesity, Heart Failure
Interventions
NNC0487-0111, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
5,610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
206
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF

NCT03876223
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

NCT05919342
View directory record Official record
Conditions
Heart Failure, Cardiovascular Diseases
Interventions
NT-proBNP
Diagnostic Test
Lead sponsor
NHS Greater Glasgow and Clyde
Other
Eligibility
40 Years and older
Enrollment
3,904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Transitions of Care Clinic (TOCC)

NCT06937827
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
HF Kit and Follow-ups
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction

NCT04008914
View directory record Official record
Conditions
Heart Failure, Preserved Ejection Fraction
Interventions
retrospective observation
Other
Lead sponsor
Ascension Macomb-Oakland Hospital
Other
Eligibility
Not listed
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated No phase listed Observational

HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study

NCT04964817
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Venous Disease
Interventions
Not listed
Lead sponsor
Prairie Education and Research Cooperative
Industry
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)

NCT04133350
View directory record Official record
Conditions
Sleep Disorder; Breathing-Related, Heart Failure
Interventions
Active Patient Engagement
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

Precision Rehabilitation for Veterans With (HFpEF)

NCT07493915
View directory record Official record
Conditions
Heart Failure, Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Columbia VA Health Care System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease

NCT03476785
View directory record Official record
Conditions
Lv Hypertrophy, Heart Failure, Diastolic, Stiffness, Vascular
Interventions
High intensity exercise, Yoga
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07083011
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05577819
View directory record Official record
Conditions
Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
Interventions
99mTc-pyrophosphate Scintigraphy
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 4:08 AM EDT